JP2006503904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503904A5 JP2006503904A5 JP2005500014A JP2005500014A JP2006503904A5 JP 2006503904 A5 JP2006503904 A5 JP 2006503904A5 JP 2005500014 A JP2005500014 A JP 2005500014A JP 2005500014 A JP2005500014 A JP 2005500014A JP 2006503904 A5 JP2006503904 A5 JP 2006503904A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- oligonucleotide
- composition according
- hsp27
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 15
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41585902P | 2002-10-02 | 2002-10-02 | |
| US60/415,859 | 2002-10-02 | ||
| US46395203P | 2003-04-18 | 2003-04-18 | |
| US60/463,952 | 2003-04-18 | ||
| PCT/CA2003/001588 WO2004030660A2 (en) | 2002-10-02 | 2003-10-02 | Compositions for treatment of prostate and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010155315A Division JP5237996B2 (ja) | 2002-10-02 | 2010-07-08 | 前立腺及び他の癌の治療用の組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006503904A JP2006503904A (ja) | 2006-02-02 |
| JP2006503904A5 true JP2006503904A5 (enExample) | 2006-09-28 |
| JP5127138B2 JP5127138B2 (ja) | 2013-01-23 |
Family
ID=32073392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005500014A Expired - Fee Related JP5127138B2 (ja) | 2002-10-02 | 2003-10-02 | 前立腺及び他の癌の治療用の組成物及び方法 |
| JP2010155315A Expired - Fee Related JP5237996B2 (ja) | 2002-10-02 | 2010-07-08 | 前立腺及び他の癌の治療用の組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010155315A Expired - Fee Related JP5237996B2 (ja) | 2002-10-02 | 2010-07-08 | 前立腺及び他の癌の治療用の組成物及び方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (8) | US7101991B2 (enExample) |
| EP (2) | EP2216029A3 (enExample) |
| JP (2) | JP5127138B2 (enExample) |
| KR (1) | KR101142080B1 (enExample) |
| CN (1) | CN1703229B (enExample) |
| AT (1) | ATE465743T1 (enExample) |
| AU (1) | AU2003278028B2 (enExample) |
| CA (1) | CA2498026C (enExample) |
| DE (1) | DE60332363D1 (enExample) |
| DK (1) | DK1545561T3 (enExample) |
| ES (1) | ES2345330T3 (enExample) |
| IL (1) | IL167621A (enExample) |
| MX (1) | MXPA05003551A (enExample) |
| NO (2) | NO338310B1 (enExample) |
| NZ (1) | NZ538841A (enExample) |
| WO (1) | WO2004030660A2 (enExample) |
| ZA (1) | ZA200502603B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545561T3 (da) | 2002-10-02 | 2010-08-02 | Univ British Columbia | Oligonucleotider til behandling af prostata og andre cancersygdomme |
| US8691780B2 (en) * | 2005-02-17 | 2014-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby |
| US20090264502A1 (en) * | 2005-08-25 | 2009-10-22 | Bennett C Frank | Compositions and their uses directed to hsp27 |
| JP2009532017A (ja) * | 2006-02-10 | 2009-09-10 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | ＰＴＤ／ＣＰＰＳへのｄｓＲＮＡ結合ドメイン融合体によるｓｉＲＮＡの導入可能な送達 |
| US8242258B2 (en) * | 2006-12-03 | 2012-08-14 | Agilent Technologies, Inc. | Protecting groups for RNA synthesis |
| WO2008106781A1 (en) * | 2007-03-05 | 2008-09-12 | The University Of British Columbia | Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy |
| WO2008112218A2 (en) | 2007-03-12 | 2008-09-18 | Antigen Express, Inc. | Li-rnai involved li suppression in cancer immunotherapy |
| CA2656577A1 (en) * | 2008-04-14 | 2009-10-14 | The University Of British Columbia | Method for evaluation of a cancer |
| BRPI0914123A2 (pt) * | 2008-07-02 | 2015-10-20 | Enzon Pharmaceuticals Inc | antagonistas de rna que alvejam hsp27 |
| NZ616745A (en) * | 2008-07-18 | 2014-06-27 | Oncogenex Tech Inc | Antisense formulation |
| WO2011054811A1 (en) * | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| KR101217866B1 (ko) * | 2010-08-18 | 2013-01-03 | 한국원자력의학원 | 혈관신생 억제용 약학 조성물 및 혈관신생 억제용 활성물질을 스크리닝하는 방법 |
| DE102010056610A1 (de) * | 2010-12-31 | 2012-07-05 | Volker A. Erdmann | Pharmazeutische Zusammensetzung enthaltend L-DNA |
| JP5658696B2 (ja) * | 2011-02-25 | 2015-01-28 | 株式会社ファンケル | 皮膚のストレス蓄積度の評価方法 |
| CA2747509C (en) | 2011-05-12 | 2017-07-18 | Oncogenex Technologies Inc. | Treatment of pulmonary and pleural fibrosis using hsp27 inhibitors |
| US9717792B2 (en) | 2012-02-02 | 2017-08-01 | The University Of British Columbia | Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates |
| GB201204785D0 (en) | 2012-03-19 | 2012-05-02 | Queen Mary & Westfield College | Method for determining prognosis of prostate cancer in a subject |
| KR101374585B1 (ko) * | 2012-05-02 | 2014-03-17 | 연세대학교 산학협력단 | ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ |
| CN104781271B (zh) | 2012-08-20 | 2018-07-06 | 加利福尼亚大学董事会 | 具有生物可逆的基团的多核苷酸 |
| CN107073003A (zh) | 2014-07-28 | 2017-08-18 | 德累斯顿工业大学 | Hsp27的有效抑制 |
| JP7039470B2 (ja) * | 2015-11-30 | 2022-03-22 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 |
| WO2019050948A1 (en) | 2017-09-05 | 2019-03-14 | Regeneron Pharmaceuticals, Inc. | ADMINISTRATION OF A GENE EDITION SYSTEM HAVING ONLY ONE RETROVIRAL PARTICLE AND METHODS OF GENERATING AND USING |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08504766A (ja) * | 1992-12-14 | 1996-05-21 | スタート テクノロジー パートナーシップ | ドーパミン作動性神経系の病態の診断および治療に関するドーパミン受容体ｍＲＮＡに対してアンチセンスのオリゴヌクレオチドの投与 |
| IL108367A0 (en) * | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| JPH09176011A (ja) * | 1995-12-27 | 1997-07-08 | Kureha Chem Ind Co Ltd | Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤 |
| US20060008448A1 (en) * | 1996-06-11 | 2006-01-12 | Minzhen Xu | Inhibition of li expression in mammalian cells |
| JPH107559A (ja) | 1996-06-18 | 1998-01-13 | Kureha Chem Ind Co Ltd | Ｈｓｐ２７ファミリーに属するタンパク質のベルベリン誘導体含有合成抑制剤 |
| US5962262A (en) | 1997-07-25 | 1999-10-05 | Incyte Pharmaceuticals, Inc. | Human heat shock 27 like protein |
| US6703228B1 (en) | 1998-09-25 | 2004-03-09 | Massachusetts Institute Of Technology | Methods and products related to genotyping and DNA analysis |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| AU772480B2 (en) | 1999-07-19 | 2004-04-29 | University Of British Columbia, The | Antisense therapy for hormone-regulated tumors |
| WO2001070976A2 (en) * | 2000-03-21 | 2001-09-27 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| ES2432225T3 (es) * | 2001-08-23 | 2013-12-02 | Arizona Board Of Regents | Reactivos y procedimientos para terapias del músculo liso |
| DK1545561T3 (da) | 2002-10-02 | 2010-08-02 | Univ British Columbia | Oligonucleotider til behandling af prostata og andre cancersygdomme |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20090264502A1 (en) * | 2005-08-25 | 2009-10-22 | Bennett C Frank | Compositions and their uses directed to hsp27 |
| WO2008106781A1 (en) | 2007-03-05 | 2008-09-12 | The University Of British Columbia | Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy |
-
2003
- 2003-10-02 DK DK03769111.0T patent/DK1545561T3/da active
- 2003-10-02 DE DE60332363T patent/DE60332363D1/de not_active Expired - Lifetime
- 2003-10-02 AU AU2003278028A patent/AU2003278028B2/en not_active Ceased
- 2003-10-02 EP EP20100002560 patent/EP2216029A3/en not_active Withdrawn
- 2003-10-02 KR KR1020057005572A patent/KR101142080B1/ko not_active Expired - Fee Related
- 2003-10-02 ES ES03769111T patent/ES2345330T3/es not_active Expired - Lifetime
- 2003-10-02 CA CA2498026A patent/CA2498026C/en not_active Expired - Fee Related
- 2003-10-02 US US10/605,498 patent/US7101991B2/en not_active Expired - Fee Related
- 2003-10-02 NZ NZ538841A patent/NZ538841A/en not_active IP Right Cessation
- 2003-10-02 EP EP03769111A patent/EP1545561B1/en not_active Expired - Lifetime
- 2003-10-02 WO PCT/CA2003/001588 patent/WO2004030660A2/en not_active Ceased
- 2003-10-02 AT AT03769111T patent/ATE465743T1/de active
- 2003-10-02 JP JP2005500014A patent/JP5127138B2/ja not_active Expired - Fee Related
- 2003-10-02 CN CN2003801009272A patent/CN1703229B/zh not_active Expired - Fee Related
- 2003-10-02 MX MXPA05003551A patent/MXPA05003551A/es active IP Right Grant
-
2005
- 2005-03-23 IL IL167621A patent/IL167621A/en active IP Right Grant
- 2005-03-31 ZA ZA200502603A patent/ZA200502603B/en unknown
- 2005-04-27 NO NO20052055A patent/NO338310B1/no not_active IP Right Cessation
- 2005-10-28 US US11/262,388 patent/US7723312B2/en not_active Expired - Fee Related
-
2006
- 2006-06-06 US US11/422,481 patent/US7550580B2/en not_active Expired - Fee Related
-
2007
- 2007-11-30 US US11/948,195 patent/US8772470B1/en not_active Expired - Fee Related
-
2009
- 2009-04-01 US US12/416,305 patent/US7847091B2/en not_active Expired - Fee Related
-
2010
- 2010-07-08 JP JP2010155315A patent/JP5237996B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-27 US US14/288,030 patent/US9085769B2/en not_active Expired - Fee Related
-
2015
- 2015-04-29 US US14/699,360 patent/US9404109B2/en not_active Expired - Fee Related
-
2016
- 2016-04-20 NO NO20160655A patent/NO20160655A1/no not_active Application Discontinuation
- 2016-06-27 US US15/193,369 patent/US9580712B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503904A5 (enExample) | ||
| Stahel et al. | Antisense oligonucleotides for cancer therapy—an overview | |
| MX336710B (es) | Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades. | |
| MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
| EP2216029A3 (en) | Oligonucleotides for treatment of prostate and other cancers | |
| JP2002539265A5 (enExample) | ||
| JP2012085642A5 (enExample) | ||
| CY1108870T1 (el) | Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους | |
| HUP0200093A2 (en) | Trpm-2 antisense therapy | |
| JP2005530486A5 (enExample) | ||
| CN101951926A (zh) | 包含微小rna-21抑制剂的增强辐射敏感性的组合物 | |
| JP2007533742A5 (ja) | 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 | |
| WO1999015643A3 (en) | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | |
| WO2005094899A8 (en) | Clusterin antisense therapy for treatment of cancer | |
| Benson et al. | DNAzymes and cardiovascular disease | |
| RU2008125041A (ru) | миРНК ПРОТИВ МИОЗИНА VA И ДЕПИГМЕНТАЦИЯ КОЖИ | |
| EP4271392A1 (en) | Template directed immunomodulation for cancer therapy | |
| EP1451205A4 (en) | ANTISENSE THERAPY USING OLIGONUCLEOTIDES, OF WHICH ARE TARGET HUMANE KINESINGENE, FOR THE TREATMENT OF CANCER | |
| Chen | Clinical development of antisense oligonucleotides as anti-cancer therapeutics | |
| Kausch et al. | Antisense oligonucleotide therapy in urology | |
| TW200504210A (en) | A nucleolin antisense inhibiting growth of cancer cell | |
| Santhosh et al. | Ovarian solid tumors: current treatment and recent developments using stimuli-responsive polymers: a systemic review | |
| JP2007517498A5 (enExample) | ||
| PL1618195T3 (pl) | Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe | |
| ATE391777T1 (de) | Verwendung von prohibitin-rns in krebsbehandlung |